Iterum Therapeutics plc — Director's Dealing 2018

May 30, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-30

Reporting Person: Fishman Corey N. (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-30	Ordinary Shares	C	33259	—	Acquired	229312	Direct
2018-05-30	Ordinary Shares	C	4050	—	Acquired	233362	Direct
2018-05-30	Ordinary Shares	C	1591	—	Acquired	234953	Direct
2018-05-30	Ordinary Shares	P	3000	$13.00	Acquired	237953	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-30	Series A Preferred Shares	$	C	33259	Disposed		Ordinary Shares (33259)	Direct
2018-05-30	Series B-1 Preferred Shares	$	C	4050	Disposed		Ordinary Shares (4050)	Direct
2018-05-30	Series B-2 Preferred Shares	$	C	1591	Disposed		Ordinary Shares (1591)	Direct

Footnotes

F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F3: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4: Not applicable.